Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells

BACKGROUND: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as v...

Descripción completa

Detalles Bibliográficos
Autores principales: Merz, Patrick R., Röckel, Nina, Ballikaya, Seda, Auffarth, Gerd U., Schmack, Ingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288953/
https://www.ncbi.nlm.nih.gov/pubmed/30537942
http://dx.doi.org/10.1186/s12886-018-0978-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288953/
https://www.ncbi.nlm.nih.gov/pubmed/30537942
http://dx.doi.org/10.1186/s12886-018-0978-9

Ejemplares similares